United Therapeutics Corp (UTHR) Financials
Key financial figures for United Therapeutics Corp (Q2 2026).
United Therapeutics Corporation reported revenue of $783.3 million for Q2 FY2026, down 1.9% from the same period a year earlier. Net income was $333.0 million, or $7.27 per share. Operating margin came to 42.23%, against 45.64% a year earlier. Free cash flow for the period was $205.6 million. Across the last 5 reported quarters, quarterly revenue has moved from $798.6 million in Q2 FY2025 to $783.3 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for United Therapeutics Corporation are on the SentiSense financials page.
- Revenue
- $783M
- Net Income
- $333M
- EPS
- $7.82
- Total Assets
- $7.2B
- Operating Cash Flow
- $314M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $783M | $333M | $7.27 | 42.23% | $206M |
| Q1 FY2026 | $782M | $275M | $5.82 | 41.69% | $363M |
| Q4 FY2025 | $790M | $364M | $7.66 | 45.24% | $173M |
| Q3 FY2025 | $800M | $339M | $7.16 | 48.69% | $352M |
| Q2 FY2025 | $799M | $310M | $6.41 | 45.64% | $130M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $3.2B | $1.3B | $27.86 | 47.67% | $1.0B |
| FY2024 | $2.9B | $1.2B | $24.64 | 47.86% | $1.1B |
| FY2023 | $2.3B | $985M | $19.81 | 50.91% | $748M |
Frequently asked questions
What was United Therapeutics Corporation's revenue last quarter?
United Therapeutics Corporation reported revenue of $783.3 million for Q2 FY2026, down 1.9% from the same period a year earlier.
Is United Therapeutics Corporation profitable?
Yes. United Therapeutics Corporation reported net income of $333.0 million for Q2 FY2026, a net margin of 42.51% on revenue.
How has United Therapeutics Corporation's margin trended?
Operating margin was 42.23% in Q2 FY2026, compared with 45.64% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did United Therapeutics Corporation generate?
United Therapeutics Corporation generated free cash flow of $205.6 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for United Therapeutics Corp on SentiSense, with up to forty quarters and twenty fiscal years of history.